Merck & Co. stock costs EUR 129.19 before October 29 results

Published on 10/20/2026 at 11:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

October 29 brings Merck's third-quarter report. Merck & Co. stock costs EUR 129.19 on October 20, 2026 versus the EUR 129.20 Xetra close.

Merck's October calendar

At West Point, Merck inaugurated a USD 550 million research facility on October 14, 2026.
Second-quarter sales reached USD 16.61 billion in Q2 2026.
Merck & Co. stock trades at EUR 129.19 at 11:17 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.01 percent below the Xetra close of October 19, 2026.
The next earnings call starts at 9:00 a.m. ET on October 29, 2026.

Black and white documentary photograph of a scientist in protective gloves and mask working inside a laminar flow biosafety cabinet. Precise hands pipette cell culture medium into multi-well plates. CO2 incubators line the background in dramatic side-lit — Merck US58933Y1055 Zellkultur schwarzweiß: Forscherin pipettiert konzentriert in steriler Biosicherheitswerkbank, dokumentarische Reportage, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was trading at EUR 129.19 at Lang & Schwarz on October 20, 2026 at 11:17 a.m. CEST, 0.01 percent below the EUR 129.20 Xetra close of October 19, 2026. The next quarterly report is scheduled for October 29, giving investors a near-term test of sales growth and the company's product pipeline.

Three milestones shape the setup

Merck's second-quarter 2026 worldwide sales were USD 16.61 billion, according to the company's investor-relations page. On October 13, 2026, the company announced first-time pivotal Phase 3 results from three oncology trials at the European Society for Medical Oncology Congress. The figures and event details appear on Merck.

On October 14, 2026, Merck inaugurated its ADVANCE bioanalytical facility in Pennsylvania. The project forms part of a USD 550 million investment in research and development facilities, according to Merck.

What does October 29 put on the line?

MarketBeat expects third-quarter 2026 revenue of USD 17.29 billion and earnings of USD 2.09 per share, compared with USD 17.28 billion and USD 2.58 per share in the year-ago quarter. Its estimates point to nearly unchanged sales but lower earnings, placing more weight on the performance of newer products and the company's forward outlook. The estimates are reported by MarketBeat.

October dates for the pipeline

Merck's investor-relations calendar lists an Investor Event at ESMO 2026 for October 26, 2026. The company also announced on October 1, 2026, that its third-quarter sales and earnings conference call will begin at 9:00 a.m. ET on October 29, 2026, according to Merck.

Stock holds near the yearly high

At EUR 129.19, the Lang & Schwarz price was EUR 5.87 below the 52-week high of EUR 135.06 and well above the 52-week low of EUR 71.30, both as of October 20, 2026. The modest daily gap to the Xetra close leaves the October 26 oncology event and the October 29 results as the clearest scheduled tests for the valuation.

Merck & Co. was trading at EUR 129.19 at Lang & Schwarz on October 20, 2026 at 11:17 a.m. CEST, 0.01 percent below the Xetra close of October 19, 2026 at EUR 129.20. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.